# Apelin Levels in HFrEF and Association with Sustained VT Detected by ICD Interrogation: A Retrospective Pilot Study

**Authors:** Abdullah Eren Cetin, Mustafa Lutfullah Ardic, Fadime Koca, Hilmi Erdem Sumbul, Mevlut Koc

PMC · DOI: 10.3390/jcdd13020079 · Journal of Cardiovascular Development and Disease · 2026-02-04

## TL;DR

This study found that lower apelin levels are linked to ventricular tachycardia in heart failure patients.

## Contribution

This is the first study to show a link between apelin levels and sustained ventricular tachycardia in HFrEF patients.

## Key findings

- Apelin levels were significantly lower in HFrEF patients with or without VT compared to controls.
- Lower apelin levels independently predicted the presence of VT in HFrEF patients.
- A cut-off apelin level of 0.80 ng/mL distinguished VT status with good accuracy.

## Abstract

Introduction: The serum apelin level in patients with heart failure with reduced ejection fraction (HFrEF) and its relationship with ventricular tachycardia (VT) are not clearly known. This study aimed to investigate changes in serum apelin levels in patients with HFrEF and their relationship with VT. Method: This retrospective pilot study included 90 patients with 30 patients in each group: Group I: HFrEF with documented VT; Group II: HFrEF without VT; Group III: control group without HFrEF. In addition to routine parameters, apelin levels were measured. All parameters were compared between Group I–II–III. Parameters associated with VT were identified. Result: Apelin levels were found to be significantly lower in Group I–II than in Group III. Serum glucose, creatinine, and left atrial diameter were shown to be significantly higher in Group I–II than in Group III. HDL cholesterol and left ventricular ejection fraction (LVEF) levels were significantly lower in Group I–II compared with Group III. A positive and negative correlation was found between plasma apelin levels and LVEF and age, respectively. In logistic regression analysis, apelin levels and LVEF were found to independently determine VT (OR = 0.313, 95%CI: 0.124–0.788, p = 0.014 and OR = 0.912, 95%CI: 0.877–0.968, p < 0.001). In the ROC analysis, the cut-off value for apelin was determined to be 0.80 ng/mL, and it distinguished VT status in this sample with acceptable sensitivity and specificity. Discussion: According to the results of our study, apelin levels are significantly reduced in patients with HFrEF, and reduced apelin levels are associated with the presence of VT in these patients.

## Linked entities

- **Diseases:** heart failure (MONDO:0005252), ventricular tachycardia (MONDO:0005477)

## Full-text entities

- **Genes:** APLNR (apelin receptor) [NCBI Gene 187] {aka AGTRL1, APJ, APJR, HG11}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, APLN (apelin) [NCBI Gene 8862] {aka APEL, XNPEP2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** volume overloaded (MESH:D019190), myocardial disease (MESH:D004194), injury to (MESH:D014947), shock (MESH:D012769), hemorrhagic stroke (MESH:D000083302), malignancy (MESH:D009369), ischemic (MESH:D002545), chronic obstructive pulmonary disease (MESH:D029424), aortic or mitral valve disease (MESH:D008946), tachycardia (MESH:D013610), aortic stenosis (MESH:D001024), Arrhythmia (MESH:D001145), atrial fibrillation (MESH:D001281), coagulation disorders (MESH:D001778), cardiovascular diseases (MESH:D002318), infection (MESH:D007239), myocardial infarction (MESH:D009203), hepatic or renal disease (MESH:D007674), heart failure (MESH:D006333), ICD (MESH:D057873), HFrEF (MESH:D054143), VT (MESH:D017180), VF (MESH:D014693)
- **Chemicals:** triglycerides (MESH:D014280), nitric-oxide (MESH:D009569), cholesterol (MESH:D002784), LA (-), urea (MESH:D014508), spironolactone (MESH:D013148), creatinine (MESH:D003404), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A2C, A4C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940892/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940892/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940892/full.md

---
Source: https://tomesphere.com/paper/PMC12940892